Elevated plasma concentration of NO and cGMP may be responsible for the decreased platelet aggregation and platelet leukocyte conjugation in platelets hypo-responsive to catecholamines

Platelets

Volumn 20, Issue 8, 2009, Pages 555-565

  Koo, Yean Kyoung ^a   Kim, Jeong Mi ^a   Kim, Sun Young ^a   Koo, Yong Ja ^a   Oh, Doyeun ^b   Park, Seonyang ^a   Yun Choi, Hye Sook ^a  

^a Seoul National University   (South Korea)

^b CHA University   (South Korea)

Author keywords

ATP secretion; CGMP; NO; Platelet aggregation; Platelet leukocyte conjugation

Indexed keywords

8 BROMO CYCLIC GMP; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CATECHOLAMINE DERIVATIVE; CYCLIC GMP; LINSIDOMINE; NITRIC OXIDE;

ADULT; ARTICLE; BLOOD LEVEL; CONJUGATE; CONJUGATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; JAPANESE; KOREA; LEUKOCYTE; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; SECRETION; THROMBOCYTE AGGREGATION;

ADENOSINE TRIPHOSPHATE; ADULT; ANTIGENS, CD45; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PLATELETS; CATECHOLAMINES; CYCLIC AMP; CYCLIC GMP; FEMALE; HUMANS; LEUKOCYTES; MALE; MOLSIDOMINE; NITRATES; NITRIC OXIDE; NITRITES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; YOUNG ADULT;

EID: 73649117108     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537100903337419     Document Type: Article

References (67)

1. Xiang YZ, Kang LY, Gao XM, Shang HC, Zhang JH, Zhang BL. Strategies for antiplatelet target and agents. Thromb Res 2008;123:35-49.
2. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991;83:38-44.
3. Anfossi G, Trovati M. Role of catecholamines in platelet function: Pathophysiological and clinical significance. Eur J Clin Invest 1996;26:353-370.
4. Gawaz M, Langer H, May AE. Platelet in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
5. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997;89:1270-1278.
6. Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999;35:154-161.
7. Zeller JA, Lenz A, Eschenfelder CC, Zunker P, Deuschl G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol 2005;25:1519-1523.
8. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: A comparative study. Am J Hematol 2006; 81:753-759.
9. Izzi B, Pampuch A, Costanzo S, Vohnout B, Iacoviello L, Cerletti C, De Gaetano G. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thromb Haemost 2007;98:1276-1284.
10. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999;81:1-7.
11. Cerletti C, Evangelista V, De Gaetano G. P-selectin-beta 2-integrin cross-talk: A molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost 1999;82:787-793.
12. Martins PDA C, Zwaginga CJJ. Leukocyte-platelet aggregates: New particles reflecting and effecting cardiovascular disease. Thromb Haemost 2005;94:1120-1121.
13. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
14. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
15. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991;88:4651-4655.
16. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993;27:1380-1382.
17. Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine: Nitric oxide pathway in human platelets. Br J Pharmacol 1990;101:325-328.
18. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fässler R, Ruth P, Krombach F, Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 30,50-monophosphate kinase I. J Exp Med 1999;189:1255-1264.
19. Riba R, Sharifi M, Farndale RW, Naseem KM. Regulation of platelet guanyly cyclase by collagen: Evidence that glycoprotein VI mediates platelet nitric oxide synthesis in response to collagen. Thromb Haemost 2005;94:395-403.
20. Naseem KM, Riba R. Unresolved roles of platelet nitric oxide synthase. J Thromb Haemost 2008;6:10-19.
21. Hines LM, Tabakoff B. WHO/ISBRA study on state and trait markers of alcohol use and dependence investigators. Platelet adenylyl cyclase activity: A biological marker for major depression and recent drug use. Biol Psychiatry 2005; 58:955-962.
22. Fisch A, Michael-Hepp J, Meyer J, Darius H. Synergistic interaction of adenylate cyclase ativators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol 1995;289:455-461.
23. Wang TY, Hussey CV, Sasse EA, Fobian JE. Human platelet aggregation and cAMP system - cAMP level, adenyl cyclase, phosphodiesterase. Ann Clin Lab Sci 1978; 8:403-412.
24. Feoktistov IA, Paul S, Hollister AS, Robertson D, Biaggioni I. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation. Am J Hypertens 1992;5:147S-153S.
25. Bruce JI, Straub SV, Yule DI. Crosstalk between cAMP and Ca2+ signaling in non-excitable cells. Cell Calcium 2003;34:431-444.
26. Kambayashi J, Shinoki N, Nakamura T, Ariyoshi H, Kawasaki T, Sakon M. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 1996;81:85-90.
27. Nakamura T, Ariyoshi H, Kambayashi J, Ikeda M, Shinoki N, Kawasaki T, Monden M. Signal transduction system in epinephrine stimulated platelets; comparison between epinephrine sensitive and insensitive platelets. Thromb Res 1997;85:83-93.
28. Pyo MK, Yun-choi HS, Hong YJ. Apparent heterogeneous responsiveness of human platelet rich plasma to catecholamines. Platelets 2003;14:171-178.
29. Kim JM, Koo YK, Heo JE, Park S, Yun-choi HS. Reduced GPIIb/IIIa expression in platelets hyposensitive to catecholamines when activated with TRAP. Thromb Res 2009; 124:90-95.
30. Nakahashi TK, Kambayashi J, Nakamura T, Le SN, Yoshitake M, Tandon NN, Sun B. Platelets in Nonresponders to epinephrine stimulation showed reduced response to ADP. Thromb Res 2001;104:127-135.
31. Redlich H, Vickers J, Lösche W, Heptinstall S, Kehrel B, Spangenberg P. Formation of platelet-leukocyte conjugates in whole blood. Platelets 1997;8:419-425.
32. McNicol A. Platelet preparation and estimation of functional response, In: Watson SP, Authi KS, editors. Platelets-A Practical Approach. London: Oirl Press, Axford University Press; 1996. pp 1-13.
33. Boo YC, Tressel SL, Jo H. An improved method to measure nitrate/nitrite with an NO-selective electrochemical sensor. Nitric oxide 2007;16:306-312.
34. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci 1993; 90:8103-8107.
35. Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res 2005;39:797-815.
36. Beckman JA, Creager MA, Libby P. Pathophysiology and management: Diabetes and atherosclerosis: epidemiology. J Am Med Assoc 2002;287:2570-2581.
37. Ouviñ a SM, La Greca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001;102:107-114.
38. Fateh-Moghadam S, Htun P, Tomandl B, Sander D, Stellos K, Geisler T, Langer H, Walton K, Handschu R, Garlichs C, et al. Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost 2007;97:974-978.
39. Gawaz M, Bogner C. Changes in platelet membrane glycoproteins and platelet-leukocyte interaction during hemodialysis. Clin Investig 1994;72:424-429.
40. Ehlers R, Ustinov V, Chen Z, Zhang X, Rao R, Luscinskas FW, Lopez J, Plow E, Simon DI. Targeting Platelet- Leukocyte Interactions: Identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ib. J Exp Med 2003;198:1077-1088.
41. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104: 1533-1537.
42. Hagberg IA, Lyberg T. Evaluation of circulating plateletleukocyte conjugates: A sensitive flow cytometric assay well suited for clinical studies. Platelets 2000;11:151-160.
43. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001;115:451-459.
44. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 2002;24:81-88.
45. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-530.
46. Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, Totani L, Piccardoni P, Vestweber D, De Gaetano G, Cerletti C. Platelet/polymorpho-nuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: Role of PSGL-1 as a signaling molecular. Blood 1999; 93:876-885.
47. Li N, Hu H, Lindqvist M, Wikstrom-jonsson E, Goodall AH, Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000;20:2702-2708.
48. Mcever RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746-756.
49. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-2171.
50. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004;61:498-511.
51. Goubareva I, Gkaliagkousi E, Shah A, Queen L, Ritter J, Ferro A. Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyteplatelet aggregates. Cardiovasc Res 2007;75:793-802.
52. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002;13:401-406.
53. Caron A, Théorêt JF, Mousa SA, Merhi Y. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardi Pharm 2002;40:296-306.
54. Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J. Effects of endotheliumderived relaxing factor/nitric oxide on platelet surface glycoproteins. Am J Physiol 1996;270:H1640-H1648.
55. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997;100:350-356.
56. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, De Wit C, Wagner K, Labugger R, Kelmi M, Noll G, Rulicke T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci 2000;97:11609-11613.
57. Minamino T, Kitakaze M, Sato H, Asanuma H, Funaya H, Koretsune Y, Hori M. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997;17: 3191-3195.
58. Yoon Y, Sonh J, Hong SH, Kim JQ. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clinic Chem 2000;46:1626-1630.
59. Levenson J, Pernollet MG, Iliou MC, Devynck MA, Simon A. Cyclic GMP release by acute enhanced external counterpulsation. Am J Hypertens 2006;19:867-872
60. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000;101:2144-2148.
61. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: A role for nitric oxide and angiotensin II. Circ Res 1999;84:417-423.
62. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 1996;32:743-751.
63. Radomki MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci 1990;87:5193-5197.
64. Moncada S, Palmer RM. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Res 1991;43:109-141.
65. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993;1178: 153-175.
66. Antl M, Von Brü hl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007; 109:552-559.
67. Gkaliagkousi E, Corrigall V, Becker S, Winter P, Shah A, Zamboulis C, Ritter J, Ferro A. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J 2009; Aug 17. [Epub ahead of print].